Calcitonin gene-related peptide (CGRP) is a neuropeptide with diverse physiological
functions. Its two isoforms (α and β) are widely expressed throughout the body in sensory …

Abstract Treatment of migraine is on the cusp of a new era with the development of drugs
that target the trigeminal sensory neuropeptide calcitonin gene-related peptide (CGRP) or its …

Background Atogepant is an oral, small-molecule, calcitonin gene–related peptide receptor
antagonist that is being investigated for the preventive treatment of migraine. Methods In a …

Objective To evaluate the efficacy and safety of eptinezumab, a humanized anti-calcitonin
gene-related peptide monoclonal antibody, in the preventive treatment of episodic migraine …

Background Antibodies targeting calcitonin gene-related peptide (CGRP) or its receptor
have shown efficacy in the prevention of migraine attacks. We investigated the efficacy and …

Migraine is an extremely disabling, common neurological disorder characterized by a
complex neurobiology, involving a series of central and peripheral nervous system areas …

Background We tested erenumab, a fully human monoclonal antibody that inhibits the
calcitonin gene–related peptide receptor, for the prevention of episodic migraine. Methods …

Objective To evaluate the efficacy and safety of galcanezumab, a humanized monoclonal
antibody that selectively binds to calcitonin gene-related peptide, in the preventive treatment …

Background Fremanezumab, a humanized monoclonal antibody targeting calcitonin gene–
related peptide (CGRP), is being investigated as a preventive treatment for migraine. We …

Plaguing humans for more than two millennia, manifest on every continent studied, and with
more than one billion patients having an attack in any year, migraine stands as the sixth …